Overview

Persantine: Variation in Response Trial

Status:
Terminated
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to understand why different people respond differently to the medication Persantine. The effects of Persantine will be evaluated by performing echocardiograms, blood tests and by measuring the flow of blood in the arteries of the heart in patients undergoing a clinically indicated percutaneous coronary intervention.
Phase:
Phase 4
Details
Lead Sponsor:
UConn Health
Collaborator:
United States Department of Defense
Treatments:
Dipyridamole